Cholesterol, stroke risk, and stroke prevention.
Serum cholesterol traditionally has been considered a poor predictor of total stroke risk; however, it is associated positively with ischemic stroke risk and associated negatively with hemorrhagic stroke risk. Although studies failed to demonstrate stroke reduction using older cholesterol-lowering medications, recent study of the statin class of medications shows both consistent stroke and other cardiovascular benefits. Ischemic stroke and coronary heart disease share similar underlying mechanisms, likely explaining much of the therapeutic benefit from statins. Current research is directed at further determining groups of patients most likely to benefit from lipid reduction in stroke prevention. In the interim, patients with established atherosclerosis should be treated with a statin to achieve a low-density lipoprotein cholesterol level less than 100 mg/dL.
Ansell
B J
BJ
UCLA School of Medicine, Department of Internal Medicine, Division of General Internal Medicine/Health Services Research, 200 UCLA Medical Plaza, Suite 370-8, Los Angeles, CA 90095, USA.
D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood* / Q000502:physiology; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy*; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*
D000924:Anticholesteremic Agents; D002784:Cholesterol